Ghent University Academic Bibliography

Show Sort by

Your filters: cql: jcr.category exact "HEMATOLOGY"

Add to list
- Journal Article
- A1
- open access
ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms

Steven Goossens (UGent) , Jueqiong Wang, Cedric Tremblay, Jelle De Medts (UGent) , Sara T'Sas (UGent) , Thao Nguyen, Jesslyn Saw, Katharina Haigh, David J Curtis, Pieter Van Vlierberghe (UGent) , et al.

(2019) HAEMATOLOGICA. 104(8). p.1608-1616
Add to list
- Journal Article
- A1
- open access
Biomolecular consequences of platelet pathogen inactivation methods

Hendrik Feys (UGent) , Britt Van Aelst and Veerle Compernolle (UGent)

(2019) TRANSFUSION MEDICINE REVIEWS. 33(1). p.29-34
Add to list
Impact of a hematopoietic stem cell transplantation on dental development

Laure Ruyssinck, Kaat Toulouse (UGent) , Maria Bordon Cueto De Braem (UGent) , Rita Cauwels (UGent) and Catharina Dhooge (UGent)

(2019) BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. 25(1). p.107-113
Add to list
Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia

Gloria Milani (UGent) , Filip Matthijssens (UGent) , Wouter Van Loocke (UGent) , Kaat Durinck (UGent) , Juliette Roels (UGent) , Sofie Peirs (UGent) , Morgan Thénoz (UGent) , Tim Pieters (UGent) , Lindy Reunes (UGent) , Béatrice Lintermans (UGent) , et al.

(2019) BRITISH JOURNAL OF HAEMATOLOGY. 185(1). p.169-174
Add to list
Granulocyte colony-stimulating factor and respiratory status of critically ill neutropenic patients with hematologic malignancies

Xavier Mignard, Lucie Biard, Virginie Lemiale, Djamel Mokart, Frédéric Pène, Achille Kouatchet, Julien Mayaux, François Vincent, Martine Nyunga, Fabrice Bruneel, et al.

(2019) LEUKEMIA & LYMPHOMA. 60(5). p.1156-1163
Add to list
- Conference Paper
- C3
Ixazomib, Rituximab and Dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom's macroblobulinemia : results of the prospective phase I/II hovon 124/Ecwm-R2 trial

Marie Jose Kersten, Monique C. Minnema, Josephine M. Vos, Kazem Nasserinejad, Marcel Kap, Eftathios Kastritis, Maria Gavriatopoulou, Martine E. D. Chamuleau, Dries Deeren, Lidwine Winnifred, et al.

(2019) BLOOD. 134(Suppl 1).
Add to list
- Conference Paper
- C3
Phase 2 results of the iR(2) Regimen (Ibrutinib, Lenalidomide, and Rituximab) in patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M. Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, et al.

(2019) BLOOD. 134(Suppl 1).
Add to list
Hypertension management in older and frail older patients

Athanase Benetos, Mirko Petrovic (UGent) and Timo Strandberg

(2019) CIRCULATION RESEARCH. 124(7). p.1045-1060
Add to list
- Conference Paper
- C3
Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma

J. Gribben, M. Trneny, K. Izutsu, N. H. Fowler, X. Hong, J. Zhu, H. Zhang, Fritz Offner (UGent) , A. Scheliga, G. Nowakowski, et al.

(2019) BRITISH JOURNAL OF HAEMATOLOGY. 185. p.79-79
Add to list
Clinical implications of measurable residual disease in AML : review of current evidence

Ine Moors (UGent) , Karl Vandepoele (UGent) , Jan Philippé (UGent) , Dries Deeren, Dominik Selleslag, Dimitri Breems, Nicole Straetmans, Tessa Kerre (UGent) and Barbara Denys (UGent)

(2019) CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 133. p.142-148

Academic Bibliography

ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms

Biomolecular consequences of platelet pathogen inactivation methods

Impact of a hematopoietic stem cell transplantation on dental development

Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia

Granulocyte colony-stimulating factor and respiratory status of critically ill neutropenic patients with hematologic malignancies

Ixazomib, Rituximab and Dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom's macroblobulinemia : results of the prospective phase I/II hovon 124/Ecwm-R2 trial

Phase 2 results of the iR(2) Regimen (Ibrutinib, Lenalidomide, and Rituximab) in patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Hypertension management in older and frail older patients

Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma

Clinical implications of measurable residual disease in AML : review of current evidence

Contents

Support

Contact